Skip to main content
Clinical Trials/DRKS00006083
DRKS00006083
Completed
Not Applicable

Cross-sectional Evaluation of clinical symptoms and epidemiologic parameters in patients with TMA, differentiated by laboratory param-eters (CESAR) - CESAR

Alexion Pharma Germany GmbH0 sites232 target enrollmentApril 23, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
D59.3
Sponsor
Alexion Pharma Germany GmbH
Enrollment
232
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 23, 2014
End Date
March 29, 2017
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. microangiopathic hemolytic anaemia, 2\. thrombocytopenia: thrombocytes \< 150 x 10´\`9/l or thrombocytes decreased by more than 25% during one week, 3\. One of the following: neurological symptoms, renal dysfunction, gastrointestinal symptoms

Exclusion Criteria

  • plasma intervention before blood sampling, antibiotic therapy before stool sampling

Outcomes

Primary Outcomes

Not specified

Similar Trials